Therefore, if we assume that the anti-tumor effect of erlotinib is mostly mediated by EGFR inhibition, it is theoretically possible to reduce the risk of skin rash with a negligible loss in therapeutic effect by optimizing the dose to inhibit EGFR but not STK-10. This evidence concerns the gene EGFR and neoplasm.